Lyell Immunopharma, Inc. (LYEL) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$36.0K

Net Income/Loss (FY2025)

-$274.4M

Total Assets (FY2025)

$340.1M

Total Equity (FY2025)

$248.2M

Cash Flows from Operating Activities (FY2025)

-$150.0M

Source: Lyell Immunopharma, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.